Plasma Derived Therapy Market Outlook:
Plasma Derived Therapy Market size was valued at USD 24.31 billion in 2025 and is likely to cross USD 48.27 billion by 2035, expanding at more than 7.1% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of plasma derived therapy is assessed at USD 25.86 billion.
The number of people suffering from rare diseases is growing to a great extent due to which demand for therapeutic treatments is increasing such as plasma-derived therapy. As per recent data provided by Global Genes, around 400 million people are suffering from rare diseases across the world and 95% of these diseases lack FDA approval for treatment.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of plasma derived therapy is assessed at USD 25.86 billion.
The global plasma derived therapy market size was valued at over USD 24.31 billion in 2025 and is expected to expand at a CAGR of around 7.1%, surpassing USD 48.27 billion revenue by 2035.
North America plasma derived therapy market will hold more than 44% share by 2035, fueled by government and private initiatives encouraging therapeutic systems.
Key players in the market include CSL Behring, ADMA Biologics, Inc., Bio Products Laboratory Ltd., Biotest AG, Grifols, SA, Kedrion S.p.A, Octapharma AG, Pfizer Inc., SK Plasma, Kamada Pharmaceuticals.
